Vancocin Related Published Studies
Well-designed clinical trials related to Vancocin (Vancomycin)
Health economic evaluation of patients treated for nosocomial pneumonia caused by
methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter
randomized clinical trial of vancomycin and linezolid. [2014]
Resolution of Clostridium difficile-associated diarrhea in patients with cancer
treated with fidaxomicin or vancomycin. [2013]
Randomised clinical trial: vancomycin or metronidazole in patients with primary
sclerosing cholangitis - a pilot study. [2013]
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and
Candida species in patients treated with fidaxomicin versus vancomycin for
Clostridium difficile infection. [2012]
Meta-analysis of randomized controlled trials of vancomycin for the treatment of
patients with gram-positive infections: focus on the study design. [2012]
Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan. [2011.04]
Fidaxomicin versus vancomycin for Clostridium difficile infection. [2011.02.03]
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. [2011.01.01]
Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam
in the treatment of complicated skin and skin structure infections in patients
from India and Taiwan. [2011]
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive
pathogens. [2011]
ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. [2010.12]
Retrospective cohort study of hospitalized adults treated with vancomycin or clindamycin for methicillin-resistant Staphylococcus aureus skin infections. [2010.11]
Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study. [2010.08]
Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans. [2010.07]
Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. [2010.06]
Comparison of continuous infusion versus intermittent infusion of vancomycin in patients with methicillin-resistant Staphylococcus aureus. [2010.02]
Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. [2010.01]
[Linezolid versus vancomycin in the treatment of pneumonia caused by
Gram-positive cocci: meta-analysis of randomised controlled trials]. [Article in Chinese] [2010]
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized,
double-blind studies to evaluate the safety and efficacy of ceftaroline versus
vancomycin plus aztreonam in complicated skin and skin-structure infection. [2010]
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. [2009.06]
The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. [2009.03]
Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. [2009.02.15]
Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A Randomized, Double-Blind Study. [2009.01.09]
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. [2008.12]
Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. [2008.12]
Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. [2008.09]
Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic? [2008.05.15]
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. [2008.04]
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. [2008.03.01]
Efficacy and safety study of fixed-dose combination of ceftriaxone-vancomycin injection in patients with various infections. [2008.01]
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. [2007.08.01]
Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy. [2007.08]
Successful prevention of tunneled, central catheter infection by antibiotic lock therapy using vancomycin and gentamycin. [2007.06]
Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. [2007.05.07]
Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. [2007.01.15]
What to think if the results of the National Institutes of Health randomized trial of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus control measures are negative (and other advice to young epidemiologists): a review and an au revoir. [2006.10]
Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. [2006.08.15]
Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. [2006.08]
Prospective randomized controlled trial of the effect of intracameral vancomycin and gentamicin on macular retinal thickness and visual function following cataract surgery. [2006.05]
Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. [2006.03.01]
Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). [2005.12]
Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. [2005.11]
Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. [2005.11]
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. [2005.09]
A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infection in critically ill neonates with peripherally inserted central venous catheters: a prospective, randomized trial. [2005.08]
Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. [2005.06]
Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. [2005.04]
Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. [2005.02]
Linezolid eradicates MRSA better than vancomycin from surgical-site infections. [2004.12]
A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. [2004.11.01]
Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial. [2004.06]
Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation. [2004.06]
Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. [2003.12.15]
Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. [2003.09]
Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. [2003.08.01]
Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration. [2003.08]
Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. [2003.08]
Topical vancomycin applied on closure of the sternotomy wound does not prevent high levels of systemic vancomycin. [2003.05]
Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. [2003.05]
Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. [2003.03]
Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. [2003.03]
TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. [2002.11]
Gastrointestinal transit survival of an Enterococcus faecium probiotic strain administered with or without vancomycin. [2002.07.25]
Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. [2002.06.01]
Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. [2002.06]
Comparison of vancomycin versus cefazolin as initial therapy for peritonitis in peritoneal dialysis patients. [2002.05]
[Importance of a cefpirome-vancomycin combination on bactericidal kinetics in severe MRSA infections in intensive care] [2002.04]
Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections. [2002.02]
Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. [2002.02]
Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. [2002.01]
Vancomycin levels in human aqueous humour after intravenous and subconjunctival administration. [2001.09]
[The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci] [2001.09]
Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. [2001.09]
Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium. [2001.08.15]
Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. [2001.07]
Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. [2001.03]
The effect of topical povidone-iodine, intraocular vancomycin, or both on aqueous humor cultures at the time of cataract surgery. [2001.03]
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. [2001.02.01]
[Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study] [2000.10.28]
Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia. [2000.08]
Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci. [2000.06]
Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: A randomized, multicenter, double-blind trial. [2000.03]
Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. [2000.03]
Intraocular penetration of vancomycin eye drops after application to the medial canthus with closed lids. [2000.03]
Impact on human intestinal microflora of an Enterococcus faecium probiotic and vancomycin. [2000]
Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients. [2000]
Antihistamine prophylaxis permits rapid vancomycin infusion. [1999.09]
Cystoid macular edema after cataract surgery with intraocular vancomycin. [1999.09]
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. [1999.08]
Ceftriaxone versus vancomycin prophylaxis in cardiovascular surgery. [1999.08]
A randomized trial of surgical antimicrobial prophylaxis with and without vancomycin in organ transplant patients. [1999.06]
High-dose aprotinin with gentamicin-vancomycin antibiotic prophylaxis increases blood concentrations of creatinine and cystatin C in patients undergoing coronary artery bypass grafting. [1999.04]
Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. [1999.03]
Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients. [1999.03]
Reducing vancomycin use utilizing a computer guideline: results of a randomized controlled trial. [1998.11]
Double blind, randomised, placebo controlled study of oral vancomycin in prevention of necrotising enterocolitis in preterm, very low birthweight infants. [1998.09]
Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. [1998.09]
Tryptase levels are not increased during vancomycin-induced anaphylactoid reactions. [1998.09]
Oral antihistamines reduce the side effects from rapid vancomycin infusion. [1998.09]
Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients. [1998.09]
A randomized prospective comparison of oral levofloxacin plus intraperitoneal (IP) vancomycin and IP netromycin plus IP vancomycin as primary treatment of peritonitis complicating CAPD. [1998.07]
|
